SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

(2021) · doi:10.1101/2021.01.15.426911 · Cited by 1,354

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Wu, K., Werner, A. P., Moliva, J. I., Koch, M., Choi, A., Stewart-Jones, G. B. E., Bennett, H., Boyoglu-Barnum, S., Shi, W., Graham, B. S., et al. (2021) · doi:10.1101/2021.01.25.427948 · Cited by 419

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human seraPreprint

Rathnasinghe, R., Jangra, S., Čupić, A., Martínez‐Romero, C., Mulder, L. C. F., Kehrer, T., Yildiz, S., Choi, A., Mena, I., Vrieze, J. D., et al. (2021) · medRxiv · doi:10.1101/2021.01.19.21249592 · Cited by 110

The biological and clinical significance of emerging SARS-CoV-2 variants

Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009

Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study

Ranzani, O., Hitchings, M. D. T., Dorión, M., D’Agostini, T. L., de Paula, R. C., de Paula, O. F. P., Villela, E. F. D. M., Torres, M. S. S., de Oliveira, S. B., Schulz, W. L., et al. (2021) · BMJ · doi:10.1136/bmj.n2015 · Cited by 349

SARS-CoV-2 Variants of Concern

Choi, J. Y., & Smith, D. M. (2021) · Yonsei Medical Journal · doi:10.3349/ymj.2021.62.11.961 · Cited by 319

Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2

Wu, H., Xing, N., Meng, K., Fu, B., Xue, W., Dong, P., Tang, W., Xiao, Y., Liu, G., Luo, H., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.11.005 · Cited by 229

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Chi, W.-Y., Li, Y.-D., Huang, H., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 225

Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe

Thakur, V., Bhola, S., Thakur, P., Patel, S. K. S., Kulshrestha, S., Ratho, R. K., & Kumar, P. (2022) · Infection · doi:10.1007/s15010-021-01734-2 · Cited by 195

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors

Tan, C. W., Chia, W., Young, B. E., Zhu, F., Lim, B. L., Sia, W. R., Thein, T.-L., Chen, M. I.-C., Leo, Y., Lye, D. C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108453 · Cited by 198

Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study

Hitchings, M. D. T., Ranzani, O., Torres, M. S. S., de Oliveira, S. B., Almirón, M., Said, R., Borg, R., Schulz, W. L., de Oliveira, R. D., da Silva, P. V., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100025 · Cited by 201

The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines

McLean, G. R., Kamil, J. P., Lee, B., Moore, P. L., Schulz, T. F., Muik, A., Şahin, U., Türeci, Ö., & Pather, S. (2022) · mBio · doi:10.1128/mbio.02979-21 · Cited by 195

The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation

Rajah, M. M., Bernier, A., Buchrieser, J., & Schwartz, O. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167280 · Cited by 188

SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines

Thakur, S., Sasi, S., Pillai, S. G., Nag, A., Shukla, D., Singhal, R., Phalke, S., & Velu, G. S. K. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.815389 · Cited by 167

A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations

Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.801522 · Cited by 154

Nanotechnology-based strategies against SARS-CoV-2 variants

Huang, X., Kon, E., Han, X., Zhang, X., Kong, N., Mitchell, M. J., Peer, D., & Tao, W. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01174-5 · Cited by 146

Applications of Molecular Dynamics Simulation in Protein Study

Sinha, S., Tam, B., & Wang, S. M. (2022) · Membranes · doi:10.3390/membranes12090844 · Cited by 154

SARS‐CoV‐2 variants and vulnerability at the global level

Chavda, V. P., Patel, A., & Vaghasiya, D. D. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27717 · Cited by 135

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies

Lusvarghi, S., Pollett, S. D., Neerukonda, S. N., Wang, W., Wang, R., Vassell, R. A., Epsi, N. J., Fries, A. C., Agan, B. K., Lindholm, D. A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn8543 · Cited by 133

Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection

Chaguza, C., Hahn, A. M., Petrone, M. E., Zhou, S., Ferguson, D. J. P., Breban, M. I., Pham, K., Peña-Hernández, M. A., Castaldi, C., Hill, V., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100943 · Cited by 123

Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S‐glycoprotein, infectivity, re‐infectivity, immune escape and vaccines activity

Chakraborty, C., Bhattacharya, M., & Sharma, A. R. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2270 · Cited by 111

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses

Sun, W., Liu, Y., Amanat, F., González‐Domínguez, I., McCroskery, S., Slamanig, S., Coughlan, L., Rosado, V. C., Lemus, N., Jangra, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26499-y · Cited by 108

Reinfection in patients with COVID-19: a systematic review

Ren, X., Zhou, J., Guo, J., Hao, C., Zheng, M., Zhang, R., Huang, Q. Y., Yao, X., Li, R., & Jin, Y. (2022) · Global Health Research and Policy · doi:10.1186/s41256-022-00245-3 · Cited by 104

COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions

Khan, W. H., Hashmi, Z., Goel, A., Ahmad, R., Gupta, K., Khan, N., Alam, I., Ahmed, F., & Ansari, M. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.690621 · Cited by 105

CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma

Geng, J., Chen, L., Yuan, Y., Wang, K., Wang, Y., Qin, C., Wu, G., Chen, R., Zhang, Z., Wei, D., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00760-8 · Cited by 102

SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients

Scherer, E. M., Babiker, A., Adelman, M. W., Allman, B. E., Key, A., Kleinhenz, J., Langsjoen, R. M., Nguyen, P.-V., Onyechi, I., Sherman, J. D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2202861 · Cited by 94

The success of SARS-CoV-2 vaccines and challenges ahead

Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 92

SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy

Yang, Z., Han, Y., Ding, S., Shi, W., Zhou, T., Finzi, A., Kwong, P. D., Mothes, W., & Lu, M. (2022) · mBio · doi:10.1128/mbio.03227-21 · Cited by 78

Immunity to SARS-CoV-2 up to 15 months after infection

Marcotte, H., Piralla, A., Zuo, F., Du, L., Cassaniti, I., Wan, H., Kumagai‐Braesch, M., Andréll, J., Percivalle, E., Sammartino, J. C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103743 · Cited by 83

Emerging Vaccine-Breakthrough SARS-CoV-2 Variants

Wang, R., Chen, J., Hozumi, Y., Yin, C., & Wei, G. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00557 · Cited by 82

Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo

Hitchings, M. D. T., Ranzani, O., Dorión, M., D’Agostini, T. L., de Paula, R. C., de Paula, O. F. P., Villela, E. F. D. M., Torres, M. S. S., de Oliveira, S. B., Schulz, W. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26459-6 · Cited by 78

Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients; A systematic review and meta-analysis

Ramzi, Z. S. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.10.059 · Cited by 77

E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil

Ferrareze, P. A. G., Franceschi, V. B., Mayer, A. D. M., Caldana, G. D., Zimerman, R. A., & Thompson, C. E. (2021) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2021.104941 · Cited by 82

Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape

Mast, F. D., Fridy, P. C., Ketaren, N. E., Wang, J., Jacobs, E. Y., Olivier, J. P., Sanyal, T., Molloy, K. R., Schmidt, F., Rutkowska, M., et al. (2021) · eLife · doi:10.7554/elife.73027 · Cited by 69

SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies

Gong, W., Parkkila, S., Wu, X., & Aspatwar, A. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2079642 · Cited by 75

COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern

Zeyaullah, M., AlShahrani, A. M., Muzammil, K., Ahmad, I., Alam, S., Khan, W. H., & Ahmad, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.693916 · Cited by 74

Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies

Noori, M., Nejadghaderi, S. A., Arshi, S., Carson‐Chahhoud, K., Ansarin, K., Kolahi, A., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2277 · Cited by 64

Predicting the antigenic evolution of SARS-COV-2 with deep learning

Han, W., Chen, N., Xu, X., Sahil, A., Zhou, J., Li, Z., Zhong, H., Gao, E., Zhang, R., Wang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39199-6 · Cited by 66

A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein

Ghosh, N., Nandi, S., & Saha, I. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108565 · Cited by 64

SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene

Jhun, H., Park, H., Hisham, Y., Song, C., & Kim, S. (2021) · Immune Network · doi:10.4110/in.2021.21.e32 · Cited by 65

Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients

Carreño, J. M., Alshammary, H., Singh, G., Raskin, A. J., Amanat, F., Amoako, A. A., Gonzalez-Reiche, A. S., van de Guchte, A., PARIS study group, Awawda, M. H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103626 · Cited by 61

Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India

Philomina J, B., Jolly, B., John, N., Bhoyar, R. C., Majeed, N., Senthivel, V., CP, F., Rophina, M., Vasudevan, B., Imran, M., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.05.018 · Cited by 62

Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious Impact on Pathogenesis: A Comparative Genomics Approach

Mohammad, T., Choudhury, A., Habib, I., Asrani, P., Mathur, Y., Umair, M., Anjum, F., Shafie, A., Yadav, D. K., & Hassan, M. I. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.765039 · Cited by 61

Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay

Cao, W., Cho, C.-C. D., Geng, Z. Z., Shaabani, N., Ma, X. R., Vatansever, E. C., Alugubelli, Y. R., Ma, Y., Chaki, S. P., Ellenburg, W. H., et al. (2022) · ACS Central Science · doi:10.1021/acscentsci.1c00910 · Cited by 62

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial

Toledo-Romaní, M. E., Carmenate, M. G., Valenzuela‐Silva, C., Rodríguez, W. B., Martínez-Pérez, M., Rodríguez-González, M., Paredes-Moreno, B., Mendoza-Hernández, I., González-Mugica, R., Samón-Tabío, O., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100423 · Cited by 65

Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants

Monteil, V., Eaton, B., Postnikova, E. N., Murphy, M. J., Braunsfeld, B., Crozier, I., Kricek, F., Niederhöfer, J., Schwarzböck, A., Breid, H., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115230 · Cited by 54

Could live attenuated vaccines better control COVID-19?

Okamura, S., & Ebina, H. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.018 · Cited by 61

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Clemens, S. A. C., Folegatti, P. M., Emary, K. R. W., Weckx, L. Y., Ratcliff, J., Bibi, S., Mendes, A. V. A., Milan, E. P., Pittella, A. M., Schwarzbold, A. V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25982-w · Cited by 57

Rapid and Sensitive Genotyping of SARS-CoV-2 Key Mutation L452R with an RPA-PfAgo Method

Zhao, C., Yang, L., Zhang, X., Tang, Y., Wang, Y., Shao, X., Gao, S., Liu, X., & Wang, P. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03563 · Cited by 55

SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern

Lu, M., Chamblee, M., Zhang, Y., Ye, C., Dravid, P., Park, J., Mahesh, K., Trivedi, S., Murthy, S. S., Sharma, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110105119 · Cited by 55

Direct Comparison of RT-ddPCR and Targeted Amplicon Sequencing for SARS-CoV-2 Mutation Monitoring in Wastewater

Lou, E. G., Sapoval, N., McCall, C., Bauhs, L., Carlson‐Stadler, R., Kalvapalle, P. B., Lai, Y., Palmer, K., Penn, R., Rich, W., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.155059 · Cited by 48

The challenges of COVID‐19 Delta variant: Prevention and vaccine development

He, X., He, C., Hong, W., Zhang, K., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.95 · Cited by 52

SARS-CoV-2: phenotype, genotype, and characterization of different variants

Saberiyan, M., Karimi, E., Khademi, Z., Movahhed, P., Safi, A., & Ghahfarrokhi, A. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00352-6 · Cited by 56

Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies

Laurini, E., Marson, D., Aulić, S., Fermeglia, A., & Pricl, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-99827-3 · Cited by 45

Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study

Shoukat, A., VILCHES, T. N., Moghadas, S. M., Sah, P., Schneider, E. C., Shaff, J., Zucker, J. R., Quinn, C., Chokshi, D. A., & Galvani, A. P. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100085 · Cited by 51

Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics

Newby, M. L., Fogarty, C. A., Allen, J. D., Butler, J., Fadda, E., & Crispin, M. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167928 · Cited by 49

Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis

Nissinen, R., Leirisalo-Repo, M., Peltomaa, R., Palosuo, T., & Vaarala, O. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.008599 · Cited by 50

A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS‐CoV‐2 variants and wild‐type of the virus

He, C., Yang, H. J., He, X., Hong, W., Hong, L., Chen, Z., Shen, G., Yang, L., Li, J., Wang, Z., et al. (2021) · MedComm · doi:10.1002/mco2.72 · Cited by 43

E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody

Chakraborty, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108424 · Cited by 47

SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations

Yang, W.-T., Huang, W.-H., Liao, T.-L., Hsiao, T.-H., Chuang, H.-N., & Liu, P.-Y. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s344099 · Cited by 51

Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine

Furukawa, K., Tjan, L. H., Kurahashi, Y., Sutandhio, S., Nishimura, M., Arii, J., & Mori, Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.10780 · Cited by 47

Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview

Mehra, R., & Kepp, K. P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00433 · Cited by 45

The Development of SARS-CoV-2 Variants: The Gene Makes the Disease

Pérez-Gómez, R. (2021) · Journal of Developmental Biology · doi:10.3390/jdb9040058 · Cited by 47

Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants

Yang, Z. L., Zhang, S., Tang, Y., Zhang, S., Xu, D.-Q., Yue, S., & Liu, Q. (2022) · Aging and Disease · doi:10.14336/ad.2021.1210 · Cited by 46

A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine

Jangra, S., Landers, J. J., Rathnasinghe, R., O’Konek, J. J., Janczak, K. W., Cascalho, M., Kennedy, A. A., Tai, A. W., Baker, J. R., Schotsaert, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.729189 · Cited by 44

A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection

Hassler, L., Wysocki, J. A., Gelarden, I. A., Sharma, I., Τοματσίδου, Α., Ye, M., Gula, H., Nicoleascu, V., Randall, G. C., Pshenychnyi, S., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021091209 · Cited by 44

Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2

Salleh, M. Z., Norazmi, M. N., & Deris, Z. Z. (2022) · PeerJ · doi:10.7717/peerj.13083 · Cited by 45

Alveolar macrophages: Achilles’ heel of SARS-CoV-2 infection

Wang, Z., Li, S., & Huang, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01106-8 · Cited by 48

Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern

Saha, A., Roy, S. G., Dwivedi, R., Tripathi, P., Kumar, K., Nambiar, S. M., & Pathak, R. (2025) · Vaccines · doi:10.3390/vaccines13040424 · Cited by 47

Durability of SARS-CoV-2–Specific T-Cell Responses at 12 Months Postinfection

Lu, Z., Laing, E. D., DaMata, J. P., Pohida, K., Tso, M. S., Samuels, E. C., Epsi, N. J., Dorjbal, B., Lake, C. M., Richard, S. A., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab543 · Cited by 44

Evolution of the SARS-CoV-2 genome and emergence of variants of concern

Safari, I., & Elahi, E. (2021) · Archives of Virology · doi:10.1007/s00705-021-05295-5 · Cited by 41

Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals

Klingler, J., Lambert, G. S., Itri, V., Liu, S. T. H., Bandrés, J. C., Enyindah-Asonye, G. M., Liu, X., Simon, V. R., Gleason, C., Kleiner, G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.759688 · Cited by 44

COVID-19: From emerging variants to vaccination

Senevirathne, T. H., Wekking, D., Swain, J. W. R., Solinas, C., & Silva, P. D. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.11.005 · Cited by 45

Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera

Rathnasinghe, R., Jangra, S., Ye, C., Čupić, A., Singh, G., Martínez‐Romero, C., Mulder, L. C. F., Kehrer, T., Yildiz, S., Choi, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30763-0 · Cited by 42

Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein

Tan, Z. W., Tee, W.-V., Samsudin, F., Guarnera, E., Bond, P. J., & Berezovsky, I. N. (2022) · Structure · doi:10.1016/j.str.2021.12.011 · Cited by 38

SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire

Tarke, A., Ramezani-Rad, P., Neto, T. A. P., Lee, Y., Silva‐Moraes, V., Goodwin, B., Bloom, N. I., Siddiqui, L., Avalos, L., Frazier, A., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101583 · Cited by 38

Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review

Gopinath, S., Ishak, A., Dhawan, N., Poudel, S., Shrestha, P. S., Singh, P., Xie, E., Tahir, P., Marzaban, S., Michel, J., et al. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7050081 · Cited by 39

CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern

Xiao, H., Hu, J., Huang, C., Feng, W., Liu, Y., Kumblathan, T., Tao, J., Xu, J., Le, X. C., & Zhang, H. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117000 · Cited by 39

The variants of SARS‐CoV‐2 and the challenges of vaccines

Han, X., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27513 · Cited by 37

Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1

Nchioua, R., Schundner, A., Klute, S., Koepke, L., Hirschenberger, M., Noettger, S., Fois, G., Zech, F., Graf, A., Krebs, S., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202201745 · Cited by 33

Rampant C-to-U deamination accounts for the intrinsically high mutation rate in SARS-CoV-2 spike gene

Liu, X., Liu, X., Zhou, J., Dong, Y., Jiang, W., & Jiang, W. (2022) · RNA · doi:10.1261/rna.079160.122 · Cited by 37

Molecular characterisation and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020–2022

Puenpa, J., Rattanakomol, P., Saengdao, N., Chansaenroj, J., Yorsaeng, R., Suwannakarn, K., Thanasitthichai, S., Vongpunsawad, S., & Poovorawan, Y. (2023) · Archives of Virology · doi:10.1007/s00705-022-05666-6 · Cited by 37

Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic

González-Vázquez, L. D., & Arenas, M. (2023) · Genes · doi:10.3390/genes14020407 · Cited by 44

SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response

Mileto, D., Fenizia, C., Cutrera, M., Gagliardi, G., Gigantiello, A., SILVESTRI, A. D., Rizzo, A., Mancon, A., Bianchi, M., Poli, F., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2004866 · Cited by 36

Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects

Lusvarghi, S., Wang, W., Herrup, R., Neerukonda, S. N., Vassell, R. A., Bentley, L., Eakin, A. E., Erlandson, K. J., & Weiss, C. D. (2021) · Journal of Virology · doi:10.1128/jvi.01110-21 · Cited by 33

Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody

Piepenbrink, M. S., Park, J., Deshpande, A. A., Loos, A., Ye, C., Basu, M., Sarkar, S., Khalil, A. M., Chauvin, D., Woo, J. C., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010691 · Cited by 40

Wastewater surveillance of SARS-CoV-2 genomic populations on a country-wide scale through targeted sequencing

Cancela, F., Ramos, N., Smyth, D., Etchebehere, C., Berois, M., Rodríguez, J., Rufo, C., Alemán, A., Borzacconi, L., López, J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284483 · Cited by 29

BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant

Knabl, L., Lee, H., Wieser, M., Mur, A., Zabernigg, A. F., Knabl, L., Rauch, S., Böck, M., Schumacher, J., Kaiser, N., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00083-x · Cited by 35

Molecular Basis of Mink ACE2 Binding to SARS-CoV-2 and Its Mink-Derived Variants

Su, C., He, J., Han, P., Bai, B., Li, D., Cao, J. X., Tian, M., Hu, Y., Zheng, A., Niu, S., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00814-22 · Cited by 34

Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual

Halfmann, P., Minor, N. R., Haddock, L. A., Maddox, R., Moreno, G. K., Braun, K. M., Baker, D. A., Riemersa, K. K., Prasad, A., Alman, K. J., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac104 · Cited by 36

SARS-CoV-2 variants: Impact on biological and clinical outcome

Mahilkar, S., Agrawal, S. R., Chaudhary, S., Parikh, S., Sonkar, S. C., Verma, D. K., Chitalia, V., Mehta, D., Koner, B. C., Vijay, N., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.995960 · Cited by 36

Current state of, prospects for, and obstacles to mRNA vaccine development

Aljabali, A. A. A., Bashatwah, R. M., Obeid, M. A., Mishra, V., Mishra, Y., Serrano‐Aroca, Á., Lundstrom, K. H., & Tambuwala, M. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103458 · Cited by 35

The consequences of SARS-CoV-2 within-host persistence

Sigal, A., Neher, R. A., & Lessells, R. J. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01125-y · Cited by 39

Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease‐19 pandemic

Chadha, J., Khullar, L., & Mittal, N. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15687 · Cited by 33

PARIS and SPARTA: Finding the Achilles’ Heel of SARS-CoV-2

Simon, V. R., Kota, V. K., Bloomquist, R. F., Hanley, H. B., Forgacs, D., Pahwa, S. G., Pallikkuth, S., Miller, L. G., Schaenman, J. M. D., Yeaman, M. R., et al. (2022) · mSphere · doi:10.1128/msphere.00179-22 · Cited by 28

An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif

Fang, Y., Sun, P., Xie, X., Du, M., Du, F., Ye, J., Kalveram, B., Plante, J. A., Plante, K. S., Li, B., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp9962 · Cited by 30

Rapid detection of multiple SARS-CoV-2 variants of concern by PAM-targeting mutations

Ning, B., Youngquist, B. M., Li, D. D., Lyon, C. J., Zelazny, A. M., Maness, N. J., Tian, D., & Hu, Y. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100173 · Cited by 29

Antibody escape and global spread of SARS-CoV-2 lineage A.27

Kaleta, T., Kern, L., Hong, S. L., Hölzer, M., Kochs, G., Beer, J., Schnepf, D., Schwemmle, M., Bollen, N., Kolb, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28766-y · Cited by 33

Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates

He, Q., Mao, Q., Peng, X., He, Z., Lu, S., Zhang, J., Gao, F., Bian, L., An, C., Yu, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00926-y · Cited by 31

Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic

Li, X., Zhang, L., Chen, S. E., Ji, W., Li, C., & Ren, L. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104971 · Cited by 30

Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine

Basile, K., Rockett, R. J., McPhie, K. A., Fennell, M., Johnson-Mackinnon, J. C., Agius, J. E., Fong, W., Rahman, H., Ko, D., Donavan, L., et al. (2022) · Viruses · doi:10.3390/v14092023 · Cited by 40

Structural Immunology of SARS ‐ CoV ‐2

Yuan, M., & Wilson, I. A. (2024) · Immunological Reviews · doi:10.1111/imr.13431 · Cited by 29

Lectin from Triticum vulgaris (WGA) Inhibits Infection with SARS-CoV-2 and Its Variants of Concern Alpha and Beta

Auth, J., Fröba, M., Große, M., Rauch, P., Ruétalo, N., Schindler, M., Morokutti-Kurz, M., Graf, P., Dolischka, A., Prieschl‐Grassauer, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910205 · Cited by 30

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination seraPreprint

Jangra, S., Ye, C., Rathnasinghe, R., Stadlbauer, D., PVI study group, Krammer, F., Simon, V. R., Martínez‐Sobrido, L., García‐Sastre, A., & Schotsaert, M. (2021) · medRxiv · doi:10.1101/2021.01.26.21250543 · Cited by 133

Neutralizing response against E484K variant after original SARS-CoV-2 infectionPreprint

Hayashi, T., Yaegashi, N., & Konishi, I. (2021) · medRxiv · doi:10.1101/2021.05.07.21256803

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628

Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage

Álvarez-Díaz, D. A., Laiton‐Donato, K., Torres, O., Ruiz-Moreno, H. A., Franco-Muñoz, C., Beltran, M. A., Mercado, M., Rueda, M. G., & Muñoz, A. L. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198629 · Cited by 8

Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies

Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009772 · Cited by 101